Drug Profile
Research programme: inflammatory disorders antibodies - Galapagos/MorphoSys
Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Galapagos NV; MorphoSys
- Class Antibodies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Osteoarthritis; Osteoporosis; Rheumatoid arthritis
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Europe (Parenteral)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Osteoarthritis in Europe (Parenteral)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Osteoporosis in Europe (Parenteral)